

**REGISTERED COMPANY NUMBER: 07842342 (England and Wales)**  
**REGISTERED CHARITY NUMBER: 1148034**

**REPORT OF THE TRUSTEES AND  
UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2017  
FOR**

**CILIOPATHY ALLIANCE  
(A COMPANY LIMITED BY GUARANTEE)**

**CILIOPATHY ALLIANCE  
(A COMPANY LIMITED BY GUARANTEE)**

**CONTENTS OF THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2017**

---

	Page
Reference and Administrative Details	1
Report of the Trustees	2 to 5
Statement of Financial Activities	6
Balance Sheet	7
Notes to the Financial Statements	8 to 12
Detailed Statement of Financial Activities	13

**CILIOPATHY ALLIANCE  
(A COMPANY LIMITED BY GUARANTEE)**

**REFERENCE AND ADMINISTRATIVE DETAILS  
FOR THE YEAR ENDED 31 MARCH 2017**

---

**Trustees**

Professor Philip Beales (Professor of Medical Genetics)  
Mrs Suzanna Claire Glen (Researcher)  
Dr Elizabeth Forsythe (Clinician)(appointed 28 February 2017)  
Dr David Miller (Chair) (Independent Consultant)  
Mr Michael Parker (Retired Actuary)  
Mr Stephen Thacker (Charity Volunteer)

**Scientific Advisory Board**

Chaired by Professor Philip Beales (Chair)

**Registered Office**

91 Royal College Street  
London  
NW1 0SE

Telephone number: 020 7387 0543  
Email address: [info@ciliopathyalliance.org](mailto:info@ciliopathyalliance.org)  
Web address: [www.ciliopathyalliance.org](http://www.ciliopathyalliance.org)

**Registered Company Number**

07842342 (England and Wales) (Incorporated 10 November 2011)

**Registered Charity Number**

1148034 (registered 10 July 2012)

**Bankers**

CAF Bank Limited  
25 Kings Hill Avenue  
West Malling  
Kent  
ME14 4JQ

**Accountants**

Fryza Bannister Financials Limited  
Chartered Certified Accountants  
The Stables  
Goblands Farm Business Centre  
Cemetery Lane  
Hadlow  
Kent  
TN11 0LT

**CILIOPATHY ALLIANCE  
(A COMPANY LIMITED BY GUARANTEE)**

**REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31 MARCH 2017**

---

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 March 2017. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015).

**INTRODUCTION**

The Ciliopathy Alliance is a global alliance of patient support groups, researchers, doctors and allied health professionals representing patients and families living with and affected by diseases caused by defects in the function or structure of cilia.

Malfunctioning cilia are known to underlie a number of often chronically disabling and sometimes life-threatening genetic conditions. They affect multiple systems, causing blindness, deafness, chronic respiratory infections, kidney disease, heart disease, infertility, obesity and diabetes.

Individual disorders caused by malfunctioning cilia are rare, but more than 100 diseases have been identified - known collectively as 'ciliopathies' - and they affect as many as one in 500 - 1,000 people.

The ciliopathies currently represented by the Ciliopathy Alliance are:

- o Alström Syndrome: ultra-rare, 700 known families worldwide (50-60 in UK) causing childhood blindness, hearing loss, heart, kidney and liver failure.
- o Bardet-Biedl Syndrome: rare, 1 in 100,000 prevalence, causing visual impairment, obesity, polydactyly, kidney abnormalities/renal failure, developmental delay, infertility.
- o Jeune Syndrome: very rare, 1 in 200,000 prevalence, causing skeletal malformations, lung/respiratory problems, renal cysts/renal failure.
- o Joubert Syndrome: very rare, 1 in 100 - 250,000 prevalence, causing ataxia (lack of muscle control), abnormal breathing pattern, sleep apnoea, abnormal eye and tongue movements.
- o Polycystic Kidney Diseases (PKD): Autosomal Dominant PKD - 1 in 1 - 4,000 prevalence, causing massive cystic kidneys and livers, kidney failure, brain aneurysms, cardiovascular disease; and the rare Autosomal Recessive PKD - 1 in 20 - 40,000 prevalence, causing kidney failure and liver fibrosis, with stunted growth.
- o Primary Ciliary Dyskinesia: 1 in 15,000 prevalence, causing upper and lower respiratory tract infection, lungs, sinuses and ears.
- o Retinitis Pigmentosa: 1 in 4,000 prevalence, causing progressive sight loss.
- o Usher Syndrome: 1 in 6 - 7,000 prevalence, causing progressive hearing and sight loss, and balance problems.



**CILIOPATHY ALLIANCE  
(A COMPANY LIMITED BY GUARANTEE)**

**REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31 MARCH 2017**

---

**OBJECTIVES AND ACTIVITIES**

**Objectives and aims**

The objects of the Ciliopathy Alliance are governed by the memorandum and articles of association and are as follows:

**'To relieve sickness and promote and protect good health of children and adults living with ciliopathies, with a view to improving their conditions of life'.**

To achieve these objects, the charity aims to:

- o Promote, support and stimulate the sharing of knowledge and understanding of ciliopathies, nationally and transnationally.
- o Encourage and facilitate communication between patients, health professionals, researchers and other organisations that support people with ciliopathies.
- o Promote awareness of ciliopathies and the respective patient organisations.
- o Promote, sponsor and/or participate in national and transnational laboratory, translational and clinical research into ciliopathies and related syndromes, with the aim of developing effective therapies and management of patients with ciliopathies.
- o Invite and encourage patient involvement in research and clinical management of ciliopathies.
- o Provide information that will benefit people with ciliopathies, in particular to those patients who do not have a condition/disease-specific support group and those in hard-to-reach geographical/ethnic communities.
- o Provide information and educational materials for health professionals and similar with the aim of improving diagnosis, clinical management and social care.
- o Communicate with/ lobby national and international governments and other relevant organisations to promote the interests of people with ciliopathies and encourage an integrated approach to their health and social care.
- o Organise conferences, symposia, workshop and similar, and support the publication and/or dissemination of information and best practice about ciliopathies.
- o Co-operate with other charities, alliances, voluntary organisations and statutory bodies to further the interests of people with ciliopathies.

**Significant activities**

**Strategic workplan**

The Ciliopathy Alliance was awarded a Big Lottery Awards For All grant to develop a 3-year strategic workplan for the charity in the UK. During 2015-16, the balance of the grant was expended on the finalisation of the workplan. During 2016-17, the workplan was used as a foundation for the development of a set of Objectives that will support the implementation of the workplan. Major headings for the objectives include: Membership Engagement, Research Prioritisation, Registries, Fundraising and Spending, Operational/governance Matters.

**Information and awareness**

During 2015-16 and 2016-17, the Ciliopathy Alliance was a member of the steering committee of CILIA 2016, the third biennial international conference on ciliopathies which was held in Amsterdam in November 2016. Several Trustees (Beales, Parker and Miller) and Miss Harris attended the conference, either in full, or for the patient engagement activities. The conference was an acknowledged success and planning for the next in the series, Cilia 2018, is underway.

The Ciliopathy Alliance website [www.ciliopathyalliance.org](http://www.ciliopathyalliance.org) continues to attract over 80,000 visitors a year, with the majority being new to the site. The site contains information on the structure and function of cilia (the most popular pages on the site) and links to the patient support groups.

During the year, Miss Harris and Professor Beales led for the charity on liaison with NHS England on plans to commission a highly specialised service for ciliopathy patients. It is hoped that the service will be commissioned by NHSE in early 2018. Miss Harris also attended meetings on rare diseases organised by Genetic Alliance/RDUK, inter alia.

**Public benefit**

All charitable activities are undertaken to further charitable purposes for public benefit. The trustees confirm they have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives, and in carrying out and planning current and future activities respectively.

**FINANCIAL REVIEW**

**Reserves policy**

The directors considered that, when combined with expected income, the charity had sufficient reserves at the year-end to fund its proposed activities during 2017-18.

**CILIOPATHY ALLIANCE  
(A COMPANY LIMITED BY GUARANTEE)**

**REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31 MARCH 2017**

---

**FINANCIAL REVIEW**

**Performance**

During the year ended 31 March 2017, the charity's income was £2,968 (2016: £6,400).

The charity incurred expenses of £1,151 (2016: £4,287) resulting in a surplus of £1,817 (2016: £2,113).

Full details of the charity's performance are set out in page 6 of the statement of financial activities to the financial statements.

**FUTURE PLANS**

The charity aims to implement its 3-year strategic workplan including completing development of objectives to support this, and the focus will then be on fundraising to implement the plan and to sustain the charity.

The website will be updated during 2017.

The Ciliopathy Alliance is a member of the steering committee of the fourth international ciliopathies conference, CILIA 2018, which will take place in Copenhagen in the autumn of 2018.

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

**Governing document**

The Ciliopathy Alliance was established as a company limited by guarantee in 2011 and registered with the Charity Commission in 2012. The charity is governed by its Memorandum and Articles of Association.

**Organisation structure and governance**

The trustees of the charity, who are the directors of the limited company, are responsible for the governance of the charity. The charity has six trustees. Trustees are appointed by the charity based on their skills and expertise. A minimum of two trustees must be present at each meeting for decisions to be made.

Trustees meet approximately quarterly and communicate by email in between meetings. Members' meetings are held regularly to allow sharing of knowledge and input into the charity's strategy.

Trustees are provided with copies of relevant Charity Commission guidance and publications, including 'The Essential Trustee', 'Charities and Public Benefit' and 'It's your decision: charity trustees and decision making'.

All trustees are required to declare interests and may be required to withdraw from relevant proceedings during a board meeting. The trustees give their time freely but may claim reasonable out of pocket expenses.

**Management**

The trustees delegate the administration and secretariat functions of the charity to Tess Harris, an independent contractor, who is the CEO of the PKD Charity (a member of the Ciliopathy Alliance). The charity's accounts were prepared by Fryza Bannister Financials Limited, a firm of Chartered Certified Accountants. The charity was exempt from the requirement to have an Independent Examination.

**Risk management**

The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error.

**MEMBERSHIP**

Membership is open to any organisation or individual worldwide who shares the vision of the charity to 'improve the quality of life for people living with ciliopathies'.

Individuals and the nominated representatives of organisations can apply for membership which is subject to the directors' approval. The directors have established classes of membership with different rights and obligations.

A membership register is maintained by the secretariat. At 31 March 2017, the members were:

**Patient Groups**

Alström Syndrome (UK)  
Bardet-Biedl Syndrome (UK)  
Jeune Syndrome (UK)  
Joubert Syndrome (UK)  
Polycystic Kidney Disease Charity (UK)  
Primary Ciliary Dyskinesia Family Support Group (UK)  
RP Fighting Blindness (UK)  
Sense (UK)



**CILIOPATHY ALLIANCE  
(A COMPANY LIMITED BY GUARANTEE)**

**REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31 MARCH 2017**

---

**MEMBERSHIP (continued)**

Dyskinesia (Belgium)  
Sensenbrenner Syndrome patient group (Poland)  
Usher Syndrome Coalition (international)

**Individuals**

Professor Phil Beales  
Dr Sonia Christou-Savina  
Dr Megan Davey  
Dr Elizabeth Forsythe  
Mrs Claire Glen  
Dr Jay Gopalakrishnan  
Dr Claire Hogg  
Dr Toby Hurd  
Dr Dan Jagger  
Dr Swadhin Jana  
Dr David Miller  
Dr Hannah Mitchison  
Dr Brian Piasecki  
Dr Ursula Rodgers  
Dr Miriam Schmidts  
Mr Stephen Thacker  
Dr Joanna Walczak-Sltulpa

**Organisations**

Cincinnati Children's Hospital  
National Institute of Sensory Organs  
Poznan University of Medical Sciences

Approved by order of the board of trustees on 13 September 2017 and signed on its behalf by:



Dr D D Miller - Trustee

**CILIOPATHY ALLIANCE**  
**(A COMPANY LIMITED BY GUARANTEE)**

**STATEMENT OF FINANCIAL ACTIVITIES**  
**(INCORPORATING AN INCOME AND EXPENDITURE ACCOUNT)**  
**FOR THE YEAR ENDED 31 MARCH 2017**

	Notes	Unrestricted fund £	Restricted fund £	2017 Total funds £	2016 Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>					
Donations and legacies	3	2,968	-	2,968	6,400
<b>Total</b>		2,968	-	2,968	6,400
<b>EXPENDITURE ON</b>					
<b>Charitable activities</b>	4				
Conferences and workshops		-	-	-	1,188
Awareness, communication and stakeholder engagement		1,151	-	1,151	3,099
<b>Total</b>		1,151	-	1,151	4,287
<b>NET INCOME</b>		1,817	-	1,817	2,113
<b>RECONCILIATION OF FUNDS</b>					
Total funds brought forward		6,672	-	6,672	4,559
<b>TOTAL FUNDS CARRIED FORWARD</b>		8,489	-	8,489	6,672

**CONTINUING OPERATIONS**

All income and expenditure has arisen from continuing activities.

The notes form part of these financial statements



**CILIOPATHY ALLIANCE**  
(A COMPANY LIMITED BY GUARANTEE)

**BALANCE SHEET**  
**AT 31 MARCH 2017**

	Notes	Unrestricted fund £	Restricted fund £	2017 Total funds £	2016 Total funds £
<b>CURRENT ASSETS</b>					
Cash at bank		9,329	-	9,329	7,622
<b>CREDITORS</b>					
Amounts falling due within one year	9	(840)	-	(840)	(950)
<b>NET CURRENT ASSETS</b>		<u>8,489</u>	<u>-</u>	<u>8,489</u>	<u>6,672</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		<u>8,489</u>	<u>-</u>	<u>8,489</u>	<u>6,672</u>
<b>NET ASSETS</b>		<u><u>8,489</u></u>	<u><u>-</u></u>	<u><u>8,489</u></u>	<u><u>6,672</u></u>
<b>FUNDS</b>	10				
Unrestricted funds				8,489	6,672
Restricted funds				-	-
<b>TOTAL FUNDS</b>				<u><u>8,489</u></u>	<u><u>6,672</u></u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2017.


The members have not required the charitable company to obtain an audit of its financial statements for the year ended 31 March 2017 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small charitable companies.

The financial statements were approved by the Board of Trustees on 13 September 2017 and were signed on its behalf by:



Dr D D Miller -Trustee

The notes form part of these financial statements

**CILIOPATHY ALLIANCE  
(A COMPANY LIMITED BY GUARANTEE)**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2017**

---

**1. GENERAL INFORMATION**

Ciliopathy Alliance is a company limited by guarantee and has no share capital. It is incorporated in England and Wales and its registered office and principal address is 91 Royal College Street, London NW1 0SE.

The principal activity of the company is disclosed in the Report of the Trustees.

**2. ACCOUNTING POLICIES**

**Basis of preparing the financial statements**

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The trustees consider it appropriate to adopt the going concern basis of accounting in preparing the annual financial statements. Sufficient reserves and ongoing voluntary income are considered sufficient to meet the financial commitments for the foreseeable future.

The trustees also consider that there are no key assumptions or estimates that need separate disclosure.

The presentational currency for the financial statements is £ sterling.

**Income**

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Donations and gifts are brought into account when received.

Grants received in relation to charitable activities, where entitlement is not conditional on the delivery of a specific performance, are recognised when the charity becomes unconditionally entitled to the grant. Where grants are related to performance and specific deliverables, these are accounted for as the charity earns the right to consideration.

**Expenditure**

Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Expenditure on charitable activities comprise costs that can be allocated directly to such activities (termed direct costs) and those costs of an indirect nature necessary to support them (termed support costs).

Included under support costs are governance costs. Governance costs include those costs associated with meeting the constitutional and statutory requirements of the charity and include costs linked to the management of the charity and the accountants fees.

Support costs (including governance costs) have been allocated to expenditure on charitable activities.

**Allocation and apportionment of costs**

All costs are allocated between expenditure categories of the Statement of Financial Activities on a basis designed to reflect the use of the resource. Costs relating to a particular activity are allocated directly, others are apportioned as follows:

Postage and stationary - usage

Administration and secretariat fees - on a time basis

Website hosting fee - pro rata based on deemed benefit

Governance costs are allocated in accordance with note 5.

**Taxation**

The charity is exempt from corporation tax on its charitable activities.



**CILIOPATHY ALLIANCE  
(A COMPANY LIMITED BY GUARANTEE)**

**NOTES TO THE FINANCIAL STATEMENTS - CONTINUED  
FOR THE YEAR ENDED 31 MARCH 2017**

**2. ACCOUNTING POLICIES - continued**

**Fund accounting**

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

**Irrecoverable vat**

Irrecoverable element of VAT is included with the item of expense to which it relates.

**Debtors**

Trade debtors are recognised at the amount due net of any trade discounts. Prepayments are valued at the amount prepaid, net of any trade discounts due.

**Creditors and provisions**

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably.

**Financial instruments**

The company has financial assets and financial liabilities only of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

**3. DONATIONS AND LEGACIES**

	2017 £	2016 £
Donations	2,968	4,000
Grants	-	2,400
	<u>2,968</u>	<u>6,400</u>

Grants received, included in the above, are as follows:

	2017 £	2016 £
Capacity building grant	-	2,400
	<u>-</u>	<u>2,400</u>

**4. CHARITABLE ACTIVITIES COSTS**

	Support costs (See note 5) £	Totals £
Awareness, communication and stakeholder engagement	1,151	1,151
	<u>1,151</u>	<u>1,151</u>

**5. SUPPORT COSTS**

	Finance £	Information technology £	Governance costs £	Totals £
Awareness, communication and stakeholder engagement	32	219	900	1,151
	<u>32</u>	<u>219</u>	<u>900</u>	<u>1,151</u>

Support costs, included in the above, are as follows:

**CILIOPATHY ALLIANCE  
(A COMPANY LIMITED BY GUARANTEE)**

**NOTES TO THE FINANCIAL STATEMENTS - CONTINUED  
FOR THE YEAR ENDED 31 MARCH 2017**

**5. SUPPORT COSTS - continued**

**Management**

	2017 Total activities £	2016 Total activities £
Postage and stationery	-	64

**Finance**

	2017 Awareness, communication and stakeholder engagement £	2016 Total activities £
Bank charges	32	-

**Information technology**

	2017 Awareness, communication and stakeholder engagement £	2016 Total activities £
Website hosting fee	219	180

**Governance costs**

	2017 Awareness, communication and stakeholder engagement £	2016 Total activities £
Trustees' expenses	47	190
Accountancy fees	840	950
Companies house fees	13	13
Strategic planning fees	-	2,400
	<u>900</u>	<u>3,553</u>

**6. TRUSTEES' REMUNERATION AND BENEFITS**

There were no trustees' remuneration or other benefits for the year ended 31 March 2017 nor for the year ended 31 March 2016.

**Trustees' expenses**

	2017 £	2016 £
Trustees' expenses	47	190

Expenses were paid to one trustee, in reimbursement of travel expenses for attending trustees' meetings.



**CILIOPATHY ALLIANCE  
(A COMPANY LIMITED BY GUARANTEE)**

**NOTES TO THE FINANCIAL STATEMENTS - CONTINUED  
FOR THE YEAR ENDED 31 MARCH 2017**

**7. STAFF COSTS**

There were no staff costs for the year ended 31 March 2017 nor for the year ended 31 March 2016.

**8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES**

	Unrestricted fund £	Restricted fund £	Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>			
Donations and legacies	4,000	2,400	6,400
<b>Total</b>	4,000	2,400	6,400
<b>EXPENDITURE ON</b>			
Charitable activities			
Conferences and workshops	1,188	-	1,188
Awareness, communication and stakeholder engagement	699	2,400	3,099
<b>Total</b>	1,887	2,400	4,287
<b>NET INCOME</b>	2,113	-	2,113
<b>RECONCILIATION OF FUNDS</b>			
Total funds brought forward			
As previously reported	1,359	-	1,359
Prior year adjustment	3,200	-	3,200
<b>As Restated</b>	4,559	-	4,559
<b>TOTAL FUNDS CARRIED FORWARD</b>	6,672	-	6,672

**9. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2017 £	2016 £
Accruals and deferred income	840	950

**10. MOVEMENT IN FUNDS**

	At 1/4/16 £	Net movement in funds £	At 31/3/17 £
<b>Unrestricted funds</b>			
General fund	6,672	1,817	8,489
<b>TOTAL FUNDS</b>	6,672	1,817	8,489

**CILIOPATHY ALLIANCE  
(A COMPANY LIMITED BY GUARANTEE)**

**NOTES TO THE FINANCIAL STATEMENTS - CONTINUED  
FOR THE YEAR ENDED 31 MARCH 2017**

**10. MOVEMENT IN FUNDS - continued**

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	2,968	(1,151)	1,817
	<u>2,968</u>	<u>(1,151)</u>	<u>1,817</u>
<b>TOTAL FUNDS</b>	<u>2,968</u>	<u>(1,151)</u>	<u>1,817</u>

**11. RELATED PARTY DISCLOSURES**

There were no related party transactions for the year ended 31 March 2017.

**12. PURPOSE OF RESTRICTED FUNDS**

The restricted fund was fully expended in the previous accounting period and related to a grant awarded to develop a 3 year work plan.

**CILIOPATHY ALLIANCE  
(A COMPANY LIMITED BY GUARANTEE)**

**DETAILED STATEMENT OF FINANCIAL ACTIVITIES  
FOR THE YEAR ENDED 31 MARCH 2017**

	2017 £	2016 £
<b>INCOME AND ENDOWMENTS</b>		
<b>Donations and legacies</b>		
Donations	2,968	4,000
Grants	-	2,400
	<u>2,968</u>	<u>6,400</u>
<b>Total incoming resources</b>	2,968	6,400
<b>EXPENDITURE</b>		
<b>Charitable activities</b>		
Conferences and workshops	-	490
<b>Support costs</b>		
<b>Management</b>		
Postage and stationery	-	64
<b>Finance</b>		
Bank charges	32	-
<b>Information technology</b>		
Website hosting fee	219	180
<b>Governance costs</b>		
Trustees' expenses	47	190
Accountancy fees	840	950
Companies house fees	13	13
Strategic planning fees	-	2,400
	<u>900</u>	<u>3,553</u>
<b>Total resources expended</b>	1,151	4,287
<b>Net income</b>	<u><u>1,817</u></u>	<u><u>2,113</u></u>

This page does not form part of the statutory financial statements